SV2017005461A - Benzamidas sustituidas con 1,3-tiazol-2-ilo - Google Patents
Benzamidas sustituidas con 1,3-tiazol-2-iloInfo
- Publication number
- SV2017005461A SV2017005461A SV2017005461A SV2017005461A SV2017005461A SV 2017005461 A SV2017005461 A SV 2017005461A SV 2017005461 A SV2017005461 A SV 2017005461A SV 2017005461 A SV2017005461 A SV 2017005461A SV 2017005461 A SV2017005461 A SV 2017005461A
- Authority
- SV
- El Salvador
- Prior art keywords
- benzamids
- tiazol
- ilo
- replaced
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
COMPUESTOS DE BENZAMIDAS SUSTITUIDAS CON 1,3-TIAZOL-2-ILO DE LA FÓRMULA GENERAL (I) QUE SE DESCRIBEN Y DEFINEN EN LA PRESENTE, CON COMPOSICIONES Y COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS Y CON EL USO DE DICHOS COMPUESTOS EN LA ELABORACIÓN DE UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO O LA PROFILAXIS DE UNA ENFERMEDAD, EN PARTICULAR DE UN TRASTORNO NEUROGÉNICO, YA SEA COMO AGENTE ÚNICO O EN COMBINACIÓN CON OTROS INGREDIENTES ACTIVOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196954 | 2014-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005461A true SV2017005461A (es) | 2018-04-30 |
Family
ID=52015966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005461A SV2017005461A (es) | 2014-12-09 | 2017-06-09 | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
Country Status (42)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2969952A1 (en) * | 2014-12-09 | 2016-06-16 | Adam James Davenport | 1,3-thiazol-2-yl substituted benzamides |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN106588785A (zh) * | 2016-12-02 | 2017-04-26 | 山东吉田香料股份有限公司 | 一种乙酰基吡嗪的制备方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| JP2021523919A (ja) | 2018-05-15 | 2021-09-09 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| BR112020022340A2 (pt) * | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
| EP3862000B1 (en) | 2018-10-05 | 2023-10-18 | Shionogi & Co., Ltd | Medicine for treating chronic cough |
| AU2019358327B2 (en) * | 2018-10-10 | 2025-04-24 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment of pruritus with P2X3 antagonists |
| CN113727716A (zh) * | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| KR20210149113A (ko) * | 2019-04-05 | 2021-12-08 | 신젠타 크롭 프로텍션 아게 | 살충 활성 디아진-아미드 화합물 |
| AU2020272472A1 (en) * | 2019-04-11 | 2021-10-28 | Syngenta Crop Protection Ag | Pesticidally active diazine-amide compounds |
| MA56022A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| MA56020A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3 |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
| AU2021282039A1 (en) * | 2020-05-25 | 2022-12-01 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Arylformamide compound and preparation method and medical use thereof |
| CN115884970B (zh) * | 2020-09-24 | 2025-09-23 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| IL301667A (en) * | 2020-09-30 | 2023-05-01 | Humanwell Healthcare Group Co Ltd | Benzamide compound and use thereof |
| JP2023550831A (ja) | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としてのフタラジン誘導体 |
| WO2022112490A1 (en) | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| AU2021386684A1 (en) | 2020-11-27 | 2023-05-25 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| CN114591317A (zh) * | 2020-12-04 | 2022-06-07 | 武汉人福创新药物研发中心有限公司 | P2x3抑制剂及其用途 |
| WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| CN116396285A (zh) * | 2022-01-04 | 2023-07-07 | 上海华汇拓医药科技有限公司 | 氘代四氢呋喃类化合物制备及其应用 |
| US12024285B1 (en) | 2022-03-10 | 2024-07-02 | Skypad Tech, Inc. | Modular mobility system including thrusters movably connected to a support structure |
| IL315933A (en) * | 2022-03-29 | 2024-11-01 | Humanwell Healthcare Group Co Ltd | P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof |
| EP4640683A1 (en) * | 2022-12-22 | 2025-10-29 | Humanwell Healthcare (Group) Co., Ltd. | Method for preparing p2x3 inhibitor |
| TW202509013A (zh) | 2023-05-22 | 2025-03-01 | 義大利商吉斯藥品公司 | 製備p2x3抑制劑之方法及中間體 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
| CN120227337A (zh) * | 2023-12-29 | 2025-07-01 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| BRPI0714315B8 (pt) | 2006-06-29 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende |
| BRPI0718714B8 (pt) * | 2006-11-09 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| US8653091B2 (en) | 2007-04-02 | 2014-02-18 | Evotec Ag | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| CA2682692A1 (en) | 2007-04-17 | 2008-10-30 | Renovis, Inc. | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| WO2008154601A1 (en) * | 2007-06-12 | 2008-12-18 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| US8461185B2 (en) | 2007-10-31 | 2013-06-11 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| ES2417182T3 (es) | 2007-12-17 | 2013-08-06 | F. Hoffmann-La Roche Ag | Nuevas arilamidas sustituidas con pirazol |
| BRPI0820838B8 (pt) | 2007-12-17 | 2021-05-25 | Hoffmann La Roche | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3 |
| ES2541662T3 (es) | 2007-12-17 | 2015-07-23 | F. Hoffmann-La Roche Ag | Derivados arilamida sustituidos con triazol y utilización de los mismos como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3 |
| CA2708791C (en) | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists |
| EP2262766B1 (en) | 2008-02-29 | 2015-11-11 | Evotec AG | Amide compounds, compositions and uses thereof |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| EP2379518B1 (en) | 2008-12-16 | 2014-05-07 | F. Hoffmann-La Roche AG | Thiadiazole-substituted arylamides |
| SG177308A1 (en) | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
| JP5465782B2 (ja) | 2009-06-22 | 2014-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | 新規オキサゾロン及びピロリジノン置換アリールアミド |
| WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| WO2014117274A1 (en) | 2013-01-31 | 2014-08-07 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| CA2969952A1 (en) * | 2014-12-09 | 2016-06-16 | Adam James Davenport | 1,3-thiazol-2-yl substituted benzamides |
| BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
| JP2021523919A (ja) | 2018-05-15 | 2021-09-09 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
-
2015
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 MX MX2017007658A patent/MX377651B/es active IP Right Grant
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja not_active Expired - Fee Related
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko not_active Withdrawn
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh not_active Expired - Fee Related
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh not_active Expired - Fee Related
- 2015-12-07 MX MX2020005909A patent/MX387478B/es unknown
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt not_active IP Right Cessation
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active Active
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en not_active Ceased
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh not_active IP Right Cessation
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
-
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
-
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
-
2019
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en not_active Expired - Fee Related
-
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
-
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2017000287A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| UY36665A (es) | Derivados de ciclohexano sustituidos con amidas | |
| DOP2016000253A (es) | Nuevos compuestos | |
| MX378386B (es) | Composiciones antiirritantes sinérgicas de taurina y aloe. | |
| NI201500118A (es) | Imidazopiridazinas sustituidas | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| MX2017003469A (es) | Inhibidores macrociclicos de cinasa rip2. | |
| CR20160369A (es) | Composiciones para uso en el tratamiento de afecciones alérgicas | |
| MX2017014128A (es) | 2-tiopirimidinonas. | |
| MX2016009567A (es) | Composicion antifungica. | |
| AR099750A1 (es) | COMPOSICIONES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA a-GLUCOSIDASA |